Neos Therapeutics, a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release products using its proprietary modified-release drug delivery technologies, announced that the US Food and Drug Administration (FDA) has approved Adzenys ER (amphetamine) extended-release oral suspension.
Neos Therapeutics is the only company to offer both branded amphetamine and methylphenidate products in extended-release dosage forms. Once commercially available, Adzenys ER oral suspension will be the third Neos extended release product for the treatment of attention deficit hyperactivity disorder (ADHD). The other Neos extended-release products for the treatment of ADHD are Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets.
“This FDA approval unlocks yet another treatment option for ADHD patients and their caregivers who are seeking a liquid extended-release amphetamine product and provides a different dosage form of our already-approved Adzenys XR-ODT,” said Vipin K. Garg, Ph.D., president and CEO of Neos Therapeutics. “Neos has now successfully gained FDA approval of three ADHD products in just two years. We are very proud of this accomplishment and believe it speaks to the strength of our technology platform. Our commitment to ADHD and addressing the individual needs of patients is clear, and we look forward to the commercial launch of this product in early 2018.”
Adzenys ER, formerly referred to as NT-0201, is a once-daily, extended-release liquid medication that does not require refrigeration or reconstitution at the pharmacy level. It utilizes the same proprietary modified-release drug delivery technology as Adzenys XR-ODT, thereby providing healthcare providers the option to transition appropriate patients from liquid to ODT formulations. Both Adzenys ER and Adzenys XR-ODT are bioequivalent to Adderall XR. Approved in January 2016, Adzenys XR-ODT is entering its second year on the market and is now the fastest growing alternative dosage form product for the treatment of ADHD.
Adzenys ER, Adzenys XR-ODT, and Cotempla XR-ODT are federally controlled substances (CII). Central nervous system (CNS) stimulants (amphetamine and methylphenidate-containing products) have a high potential for abuse and dependence. Physicians should assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence.
“It is important for physicians to have a wide choice of medicines to help our patients with ADHD manage their symptoms,” said Michael Feld, MD, a Northbrook, IL-based Child, Adolescent, and Adult Psychiatrist specializing in the treatment of ADHD. “As a once-daily liquid formulation, Adzenys ER can play a role in meeting the individual needs of my patients.”